☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC reject Rectogesic

The Scottish Medicines Consortium (SMC) has rejected Glyceryl Trinitrate 0.4% Ointment (Rectogesic)® for use on the NHS in Scotland for a second time.

This latest advice is based upon a resubmission of data after the SMC had rejected the product last year as reported here.

The SMC accept that this product is associated with a very small decrease in pain the economic case has not been demonstrated. The economic case is based on a comparison to Anacal, Anusol and Xyloproct all of which are licensed for the relief of pain associated with anal fissures. Rectogesic is about 10 times more expensive than these products.

Action: First line treatment of anal fissures should be based on lifestyle advice about diet and bowel habit. Prescriptions for products containing topical steroids or anaesthetics may be appropriate for management of pain and inflammation.

Share 'SMC reject Rectogesic' by emailShare 'SMC reject Rectogesic' on FacebookShare 'SMC reject Rectogesic' on TwitterShare 'SMC reject Rectogesic' on LinkedInShare 'SMC reject Rectogesic' on reddit


No Comments to “SMC reject Rectogesic”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.